IOVANCE BIOTHERAPEUTICS, INC. business relationships
Companies named in IOVANCE BIOTHERAPEUTICS, INC.’s 10-K filed 2026-02-24, and public companies whose annual reports name IOVANCE BIOTHERAPEUTICS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in IOVANCE BIOTHERAPEUTICS, INC.’s annual report 4
“Novartis is also entitled to low-to-mid single digit percentage royalties from commercial sales of the product.” SEC filing
“The Company recorded costs associated with the license agreement from Novartis of $ 10.0 million as research and development expenses for the year ended December 31, 2020.” SEC filing
“...nd develop TIL cell therapies in new indications in clinical trials, we currently work and collaborate with government and academic research institutions, medical institutions, and corporate partners such as the NCI, Moffitt, Memorial Sloan Kettering Cancer Center, or MSKCC, Cellectis, and Novartis.” SEC filing
“...h collaboration and exclusive worldwide license agreement whereby the Company will license gene-editing technology from Cellectis S.A. ("Cellectis"), a clinical-stage biopharmaceutical company, to develop TIL cell therapies that have been genetically edited, including a PD-1 inactivated product that...” SEC filing
Companies whose annual reports name IOVANCE BIOTHERAPEUTICS, INC. 1
“Research Collaboration and Exclusive License Agreement with Iovance Biotherapeutics” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.